Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALY II USA: MB-CART2019.1 in Relapsed/Refractory B Cell Lymphoma
NCT04792489Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of zamtocabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), central nervous system lymphoma, mantle cell lymphoma (MCL) and 1 more, sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Objective Response Rate up to 2 years. Started May 2021; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)central nervous system lymphomamantle cell lymphoma (MCL)Richter's transformation (RT)
Beyond the preview
Go deeper on NCT04792489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792489.